Real-World Evidence & Trials
Free Masterclass Live Series 2021
Join our masterclass series to learn about perspectives on real-world evidence studies from a trialist / statistician and epidemiologist / clinician, explained in clear non-technical terms and illustrated with examples from drugs and devices in multiple therapy areas.
Speakers
Key Speaker
Stuart Pocock
Professor of Medical Statistics, London School of Hygiene & Tropical Medicine
Author of > 500 papers, including 70+NEJM/Lancets, mainly of clinical trials and epidemiology; extensive experience of EMA/FDA and Data Monitoring Committee (including the Covid-19 adaptive platform DISCOVERY trial)
Chairman
Nawab Qizilbash
Senior Clinical Epidemiologist, OXON Epidemiology
Honorary Associate Professor in Pharmacoepidemiology, London School of Hygiene & Tropical Medicine and Clinical Observer, Internal Medicine, Madrid Hospitals.
Formerly: Director, Clinical Epidemiology, GSK and Honorary Consultant Physician, Radcliffe Hospitals, Oxford
Who should attend
This Masterclass series is intended for a wide audience including: Epidemiology, HEOR, Safety, Statistics, Medical Affairs, Market Access, Marketing, Project Management and Outsourcing professionals in biopharmaceutical and device companies*.
You will learn about the role and pros and cons of Real-World Data studies compared with trials.
Guidance to overcome challenges in future Real-World Data studies will be discussed with Q&A sessions for technical and non-technical questions.
Take a look at the different sessions
Don’t miss out on your chance to learn from a leading expert and register for any or all masterclasses below.
Let us know if you cannot attend any live session and we can discuss alternative arrangements.
| Title | Date | Start Time | Duration | Register |
|---|---|---|---|---|
| RWE Studies & Trials | Free Masterclass Series 2021: Live Session 4 - Individualizing Benefit-Risk SESSION 4: INDIVIDUALIZING BENEFIT-RISK Conventional methods of benefit-risk overly focus on overall results; subgroups have limitations, and the relative importance of events may not be considered. Individualizing benefit-risk more precisely would benefit identification of patients for treatment and help eligibility for future trials and RWE studies. TOPICS: • A new method of individualising benefit-risk will be introduced and explained. • Case studies will show its application from trials. • Limitations will be outlined. • Applicability to observational studies will be provided. • How this method sits with current benefit-risk models used by regulators and reimbursement agencies. • Benefits of this new method for Clinical Development, Value, Market Access, guidelines and patient management. SPEAKERS: Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine Author of more than 500 papers, including 70+NEJM/Lancets, mainly of clinical trials and epidemiology; extensive experience of EMA/FDA and Data Monitoring Committee (including the Covid-19 adaptive platform DISCOVERY trial) Nawab Qizilbash, Senior Clinical Epidemiologist, OXON Epidemiology Honorary Associate Professor in Pharmacoepidemiology, London School of Hygiene & Tropical Medicine and Clinical Observer, Internal Medicine, Madrid Hospitals. Formerly: Director, Clinical Epidemiology, GSK and Honorary Consultant Physician, Radcliffe Hospitals, Oxford DATE: June 16, 2021 at 5pm CET | 4pm UK | 11am EDT | 8am PST AGENDA: Chair: Dr Nawab Qizilbash, Senior Clinical Epidemiologist, OXON and Honorary Associate Professor, London School of Hygiene & Tropical Medicine: - Welcome and introductions (5 minutes) Key Speaker: Stuart Pocock - Programme: (45 minutes) - Q&A session (10 minutes) DETAILS: - We will be using GoToWebinar. - You can join our session by using a Mac, PC or a mobile device. | 16 Jun, 2021 | 17:00 CEST | 1 hour | Register |
